OKUR SCHEDULE 13G: SEC filing

OnKure Therapeutics, Inc.

Filed with the SEC on · accession 0001231919-26-001621

OnKure Therapeutics, Inc. (OKUR) filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 20, 2026. Venrock Healthcare Capital Partners entities and associated individuals filed a Schedule 13G reporting beneficial ownership of approximately 2,309,559 shares, or 5.7%, of OnKure Therapeutics Class A common stock.

Summary of the filing

Venrock Healthcare Capital Partners entities and associated individuals filed a Schedule 13G reporting beneficial ownership of approximately 2,309,559 shares, or 5.7%, of OnKure Therapeutics Class A common stock. The filing is a passive investment disclosure under Rule 13d-1(c).

Key details

Aggregate shares of Class A common stock beneficially owned$2.3M
Shares held by VHCP III$1.0M
Shares held by VHCP Co-Investment III$105K
Shares held by VHCP EG$1.2M
Total Class A common stock outstanding$40.5M
Reporting person / beneficial ownerVenrock Healthcare Capital Partners III, L.P.
Reporting person / beneficial ownerVHCP Co-Investment Holdings III, LLC
Reporting person / beneficial ownerVenrock Healthcare Capital Partners EG, L.P.
General partner of vhcp iii and manager of vhcp co-investment iiiVHCP Management III, LLC
General partner of vhcp egVHCP Management EG, LLC
IssuerOnKure Therapeutics, Inc.
Voting member of vhcp management iii and vhcp management egNimish Shah
Voting member of vhcp management iii and vhcp management egBong Y. Koh
Authorized signatory / attorney-in-factSherman G. Souther

✦ Ask GOAX AI about this filing — what it means for OKUR, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for OKUR?

Click here

Frequently asked questions

What did OKUR file with the SEC on Nov 20, 2026?

OKUR filed a SCHEDULE 13G (SEC filing). Venrock Healthcare Capital Partners entities and associated individuals filed a Schedule 13G reporting beneficial ownership of approximately 2,309,559 shares, or 5.7%, of OnKure Therapeutics Class A common stock. The filing is a passive investment disclosure under Rule 13d-1(c).

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

Other OKUR SEC filings

Get alerts when OKUR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days